Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
- DOI
- 10.1016/j.eclinm.2025.103338
- Published
- 2025 Jul
- Container
- EClinicalMedicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2025.103338,
title = {Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.},
author = {Zhou J and Williams C and Staplin N and Judge PK and Mayne KJ and Agrawal N and Arimoto R and Green JB and Cherney DZI and Tuttle KR and Leal J and Clarke P and Emberson JR and Preiss D and Wanner C and Landray MJ and Baigent C and Haynes R and Herrington WG and Mihaylova B and EMPA-KIDNEY Collaborative Group},
year = {2025},
journal = {EClinicalMedicine},
doi = {10.1016/j.eclinm.2025.103338},
url = {https://doi.org/10.1016/j.eclinm.2025.103338}
}RIS
TY - JOUR TI - Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. AU - Zhou J AU - Williams C AU - Staplin N AU - Judge PK AU - Mayne KJ AU - Agrawal N AU - Arimoto R AU - Green JB AU - Cherney DZI AU - Tuttle KR AU - Leal J AU - Clarke P AU - Emberson JR AU - Preiss D AU - Wanner C AU - Landray MJ AU - Baigent C AU - Haynes R AU - Herrington WG AU - Mihaylova B AU - EMPA-KIDNEY Collaborative Group PY - 2025 JO - EClinicalMedicine DO - 10.1016/j.eclinm.2025.103338 UR - https://doi.org/10.1016/j.eclinm.2025.103338 ER -
APA
J, Z., C, W., N, S., PK, J., KJ, M., N, A., R, A., JB, G., DZI, C., KR, T., J, L., P, C., JR, E., D, P., C, W., MJ, L., C, B., R, H., WG, H., B, M., & Group, E. C. (2025). Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2025.103338
Source records
- pubmed · retrieved 2026-09-25T20:29:59.915Z